The Potential of ESCO2 as a Prognostic and Immunotherapeutic Marker of Pan-Cancer and Its Role in Anti-PD-1 Treatment of Bladder Cancer
ESCO2 participates in regulating the immune infiltration and affecting the prognosis of patients in many cancers, especially in BLCA. ESCO2 may serve as a prognostic and immunotherapy biomarker in future treatment of human cancer.
Authors
- Wei Guo (ORCID: https://orcid.org/0000-0002-7644-9627)
- Shuo Zhao (ORCID: https://orcid.org/0000-0002-1239-4647)
- Jikai Liu (ORCID: https://orcid.org/0000-0001-9487-1293)
- Yidong Fan
- Keqiang Yan
Institutions
- Qilu Hospital of Shandong University (CN)
Publication Details
- Journal
- Oncology
- Published
- 2024-11-11
- DOI
- https://doi.org/10.1159/000542188
- Citations
- 2
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.84